ICON Public Limited Company's Audit Committee is investigating accounting practices and internal controls related to revenue recognition from fiscal years 2023-2025. The company disclosed material weaknesses in internal controls, delayed financial results, and withdrew 2025 guidance. ICON shares fell approximately 40% on the announcement, declining from $133.14 to $80.08 per share on February 12, 2026.
Icon Plc (ICLR)
Common Stock · Currency in USD · XNAS
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
Company Info
SIC—
Composite FIGI—
CIK0001060955
IPOMay 15, 1998
Sector—
Highlights
Market Cap$8.72B
EPS—
P/E Ratio—
Revenue—
Gross Profit—
Net Income—
Employees41,900
WSO76,359,932
Phone—
Websitehttps://www.iconplc.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Icon Plc, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Icon Plc (ICLR) has returned -37.92% so far this year and -23.48% over the past 12 months. Looking at the last ten years, ICLR has achieved an annualized return of 4.16%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
ICLR
1M5.31%
6M-41.20%
YTD-37.92%
1Y-23.48%
5Y-10.39%
10Y4.16%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Icon Plc (ICLR) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.01% | -40.01% | 4.58% | 3.03% | ||||||||
| 2025 | -6.32% | -2.15% | -2.51% | -13.90% | -8.64% | 11.76% | 16.79% | 6.15% | -0.93% | -1.65% | 9.34% | -0.86% |
| 2024 | -7.01% | 22.25% | 5.02% | -11.61% | 9.27% | -2.89% | 3.80% | -1.88% | -9.95% | -22.69% | -5.48% | -0.61% |
| 2023 | 17.14% | -1.81% | -4.62% | -9.22% | 10.56% | 17.76% | 0.87% | 4.26% | -6.20% | -0.71% | 9.36% | 6.25% |
| 2022 | -13.77% | -10.98% | 2.07% | -6.92% | 1.89% | -2.40% | 11.93% | -10.44% | -11.98% | 7.62% | 7.18% | -9.90% |
| 2021 | 3.61% | -12.04% | 5.28% | 8.70% | 2.37% | -8.83% | 16.86% | 4.18% | 2.62% | 9.93% | -6.21% | 12.86% |
| 2020 | -2.39% | -8.17% | -13.38% | 21.33% | 6.39% | 0.49% | 8.77% | -0.32% | 1.69% | -6.58% | 6.57% | -1.22% |
| 2019 | 9.34% | -0.83% | -2.96% | -0.66% | 3.40% | 8.82% | 0.43% | -1.06% | -3.88% | -0.21% | 10.44% | 5.15% |
| 2018 | -2.25% | 3.48% | 4.22% | -0.86% | 10.14% | 1.95% | 5.43% | 6.39% | 3.64% | -10.81% | 4.47% | -11.04% |
| 2017 | 10.87% | -0.78% | -5.73% | 5.61% | 11.05% | 3.43% | 7.64% | 8.51% | -0.36% | 4.32% | -1.80% | -3.43% |
| 2016 | -9.89% | 4.19% | -0.88% | 10.52% | -1.11% | 0.48% | 3.60% | -4.25% | -0.33% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Icon Plc (ICLR) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of ICLR compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Icon Plc volatility is 2.80%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
News and Insights
FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancerneutral
The FDA granted Breakthrough Therapy Designation to Johnson & Johnson's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for treating advanced, HPV-unrelated head and neck squamous cell carcinoma in adults. The drug is being evaluated in combination with Merck's Keytruda in an ongoing Phase 3 trial. Additionally, J&J extended its contract with Trellus Health for patient support services through mid-2026.
The global clinical trials support software solutions market is valued at USD 14.31 billion in 2026 and is expected to reach USD 34.15 billion by 2035, growing at a 10.15% CAGR. North America leads the market while Asia Pacific shows the fastest growth. CTMS solutions dominate by product type, cloud-based delivery leads, and CROs lead by end-user segment. Key growth drivers include increasing clinical trial complexity, adoption of decentralized trials, AI-driven analytics, and regulatory compliance demands.
Block & Leviton is investigating Gemini Space Station, Inc. (GEMI) for potential securities law violations after the company's stock fell over 10% following the sudden departure of multiple senior executives including its COO, CFO, and Chief Legal Officer. This leadership shakeup occurred months after the company's September 2025 IPO at $28 per share and follows a previously announced 25% workforce reduction plan.
Icon Plc (NASDAQ: ICLR) shares plummeted 32.55% in premarket trading after disclosing an internal accounting investigation by its Audit Committee. The probe, which began in October 2025, focuses on revenue recognition practices from 2023-2025, with preliminary findings indicating revenue may have been overstated by less than 2% in each year. The company has withdrawn its 2025 guidance and delayed financial reporting, with results expected by April 30, 2026.
Trinity Street Asset Management completely exited its position in Axalta Coating Systems, selling 770,919 shares worth approximately $22.1 million. The exit represents a full liquidation of the fund's stake in the specialty coatings company. Trinity simultaneously increased its positions in higher-growth companies like Taiwan Semiconductor Manufacturing, suggesting the fund manager sees better growth prospects in the semiconductor and technology sectors compared to the slower-growing industrial coatings industry.
The global real world evidence (RWE) solutions market is projected to grow from $5.42 billion in 2025 to $10.83 billion by 2030, with a 14.8% CAGR, driven by value-based care, chronic disease prevalence, and advancements in healthcare data analytics.
Clinical research organization ICON reported better-than-expected Q2 financial results, with quarterly sales of $2.02 billion and adjusted earnings of $3.26 per share. The company raised its fiscal 2025 sales guidance and expanded its share buyback program to $1 billion.
The global regulatory affairs outsourcing market is expected to grow significantly from 2024 to 2030, driven by the globalization of biopharmaceutical and medical device companies and the need for specialized regulatory expertise. Technological advancements in regulatory processes are also shaping the market.
Faruqi & Faruqi, LLP is investigating potential claims against ICON plc for allegedly making false and/or misleading statements about its business and financial performance, leading to significant losses for investors.